The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage. Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis. “This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients. More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s. Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice. |
Three signs Princess Charlotte's birthday portrait, taken by Kate Middleton, was not retouchedDirector spotlights rural children's soccer dreams in debut filmBeijing gears up for Strawberry Music Festival during May Day holidayCountry makes solar affordable worldwideTurkey halts all trade with Israel over military actions in GazaMan arrested in fatal shooting of Chicago police officer who was heading home from workArmy lieutenant colonel charged with smuggling firearm parts from Russia, other countriesPeter Oosterhuis, Ryder Cup stalwart and CBS announcer, dies at 75ReelFocus Project selects fresh blood for film industry's futureNebraska forward Rienk Mast will have knee surgery and miss the 2024